Medical device and MedTech insights, news, tips and more

Abbott Labs Plans to Wrap Up St. Jude Medical Deal Jan. 4 

January 3, 2017


Abbott Laboratories intends to close its deal to buy medical device maker St. Jude Medical just after the new year, now that it has received permission from U.S. and international antitrust regulators scrutinizing the $25 billion acquisition.

AbbottAbbott Labs, in suburban Chicago, said Friday it intends to wrap up the deal on Jan. 4; originally, the deal was supposed to be completed by the end of 2016. Little Canada-based St. Jude needs to grow quickly to compete with much-larger competitors like Medtronic, while Abbott is trying to fill gaps in fast-growing market segments for medical devices to treat cardiovascular disease and chronic pain.

“We continue to deliberately shape our business for long-term success by securing leadership positions in attractive markets and focusing on customer needs,” Abbott Chief Executive Miles White said in a news release Friday. “The addition of St. Jude Medical creates one of the broadest medical device portfolios in the world and provides a steady stream of new technologies and therapies for many years to come.”

Founded in 1976, St. Jude became the largest medical-device maker headquartered in Minnesota after Medtronic moved to Ireland in 2015. Roughly 4,000 of St. Jude’s 18,000 employees work in the state, including in the corporate headquarters, research and development offices and manufacturing ­facilities.

No announcements have been made about personnel changes after the deal closes.

Since announcing the deal in April, Abbott and St. Jude have undergone deep analysis by the U.S. Federal Trade Commission and regulators in Europe, China and elsewhere to make sure that the acquisition would not result in less market competition.

St. Jude and Abbott agreed to divest several proprietary devices to Japan-based Terumo Corp. for $1.1 billion as a condition of the deal, to satisfy the regulators. St. Jude will divest its Angio-Seal and Femoseal vascular closure products to Terumo, plus Abbott’s Vado steerable sheath for percutaneous procedures. Abbott will retain its own vascular closure products.

Source: Abbott Labs says it plans to wrap up St. Jude Medical deal Jan. 4 –

Author: Joe Carlson Star Tribune


More insights

March 7, 2024
FDA Clears Dexcom’s First Over-the-Counter Continuous Glucose Monitor
Learn More
March 1, 2024
FDA greenlights Boston Scientific’s Novel Drug-Coated Balloon for Coronary In-Stent Restenosis
Learn More
February 21, 2024
Sparrow BioAcoustics Launches Software That Turns a Smartphone into a Stethoscope 
Learn More

Begin your legacy now. We are your medtech and medical device talent advisory firm.